Peripheral artery disease is under scrutiny as the number of endovascular interventions has soared. In a field where clinical evidence is sparse, experts are asking how the financial and societal costs of revascularization compare with amputating the problem and whether early detection and treatment could save lives, limbs and perhaps healthcare dollars.

Trial results on same-day discharge for elective implantable cardioverter-defibrillator procedures may reassure centers, but whether the approach lowers cost is anyone’s guess.

As the supply of the radiopharmaceutical tracer isotope technetium-99m dries up, cardiologists are exploring other options for cardiovascular imaging.

ASNC looks at how a variety of healthcare trends are positioning cardiovascular PET to thrive.

JUPITER, Fla., Oct. 4, 2016 /PRNewswire/ -- Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation of new data showing the company's DuraGraft® vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery.

MISSISSAUGA, Ontario – October 3, 2016 – Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today the availability of once-daily YOSPRALA™, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA is being promoted by 110 sales representatives in the U.S. and is currently available in the wholesale chain.

CAESAREA, Israel and TAMPA, Fla., Oct. 3, 2016 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiovascular procedures, announces data recently published in the American Journal of Cardiology demonstrating new brain lesions in 94% of patients undergoing transcatheter aortic valve replacement (TAVR) by diffusion weighted magnetic resonance imaging (DWI-MRI) (n=34) prior to hospital discharge.

Marlborough, MA, October, 3, 2016 – Today, GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound contrast agent Optison™ (Perflutren protein-Type A Microspheres Injectable Suspension, USP).